Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
29 results
D2.114 - Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure
D2.115 - Occupational asthma and rhinitis to isocyanates in industrial settings
D2.105 - A Newly Identified Indoor Fungus, Fusarium hechiense, Modulates Allergic Airway Inflammation in a Murine Asthma Model
D2.107 - Genotype–Phenotype Segregation in Chronic Rhinosinusitis with Nasal Polyp and associated comorbid Asthma: Multivariate Clustering of Interleukin-4, Interleukin-6, Interleukin-13, and TNF-α Variants with Type-2 Biomarkers and Clinical Traits
D2.108 - Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents
D2.109 - Single-Cell Sequencing Reveals the Immunological Mechanism of Astragaloside IV in the Treatment of Allergic Rhinitis Complicated with Asthma
D2.110 - Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study
D2.112 - The Impact of Inflammation on Protective Immune Responses in the Airways
D2.113 - Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF25–75 Levels
D2.120 - Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update
D2.121 - Seroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download